A citation-based method for searching scientific literature

Urd Kielgast, Meena Asmar, Sten Madsbad, Jens J Holst. J Clin Endocrinol Metab 2010
Times Cited: 41







List of co-cited articles
426 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



The role of adjunctive exenatide therapy in pediatric type 1 diabetes.
Vandana S Raman, Kimberly J Mason, Luisa M Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A Heptulla. Diabetes Care 2010
60
29

Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
29


Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
21

Expression of the GLP-1 receptor in mouse, rat, and human pancreas.
Ditte Tornehave, Peter Kristensen, John Rømer, Lotte Bjerre Knudsen, R Scott Heller. J Histochem Cytochem 2008
169
21


Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
John Dupré, Margaret T Behme, Thomas J McDonald. J Clin Endocrinol Metab 2004
92
19

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
19


The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
19

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
Kristine J Hare, Tina Vilsbøll, Meena Asmar, Carolyn F Deacon, Filip K Knop, Jens J Holst. Diabetes 2010
168
17


Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiegel. J Clin Endocrinol Metab 2002
405
17

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
389
14

Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
476
14

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
J J Meier, B Gallwitz, N Siepmann, J J Holst, C F Deacon, W E Schmidt, M A Nauck. Diabetologia 2003
215
14



Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
14

Regulation of glucagon secretion by incretins.
J J Holst, M Christensen, A Lund, J de Heer, B Svendsen, U Kielgast, F K Knop. Diabetes Obes Metab 2011
92
14

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
926
14

Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
711
14



Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
14

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
14

Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes.
J Zhang, Y Tokui, K Yamagata, J Kozawa, K Sayama, H Iwahashi, K Okita, M Miuchi, H Konya, T Hamaguchi,[...]. Diabetologia 2007
55
12

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
873
12


Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.
A Hvidberg, M T Nielsen, J Hilsted, C Orskov, J J Holst. Metabolism 1994
166
12

GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis.
Yang Z De Marinis, Albert Salehi, Caroline E Ward, Quan Zhang, Fernando Abdulkader, Martin Bengtsson, Orit Braha, Matthias Braun, Reshma Ramracheya, Stefan Amisten,[...]. Cell Metab 2010
175
12

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.
L A Scrocchi, T J Brown, N MaClusky, P L Brubaker, A B Auerbach, A L Joyner, D J Drucker. Nat Med 1996
580
12

Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.
Jesper Gromada, Isobel Franklin, Claes B Wollheim. Endocr Rev 2007
398
12


Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
720
12

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE.
N MCINTYRE, C D HOLDSWORTH, D S TURNER. Lancet 1964
563
12

Effect of pioglitazone therapy in lean type 1 diabetes mellitus.
R Bhat, A Bhansali, S Bhadada, R Sialy. Diabetes Res Clin Pract 2007
30
16


Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
M A Nauck, I Vardarli, C F Deacon, J J Holst, J J Meier. Diabetologia 2011
303
12



Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.
Gayatri Sarkar, May Alattar, Rebecca J Brown, Michael J Quon, David M Harlan, Kristina I Rother. Diabetes Care 2014
51
12

Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
Prabhakar Viswanathan, Ajay Chaudhuri, Ruchi Bhatia, Fida Al-Atrash, Priya Mohanty, Paresh Dandona. Endocr Pract 2007
107
9

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
Sabine Arnolds, Sibylle Dellweg, Janina Clair, Marie-Paule Dain, Michael A Nauck, Klaus Rave, Christoph Kapitza. Diabetes Care 2010
139
9



Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.
C Orskov, L Rabenhøj, A Wettergren, H Kofod, J J Holst. Diabetes 1994
711
9

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
M B Toft-Nielsen, M B Damholt, S Madsbad, L M Hilsted, T E Hughes, B K Michelsen, J J Holst. J Clin Endocrinol Metab 2001
617
9

Impaired regulation of the incretin effect in patients with type 2 diabetes.
Jonatan I Bagger, Filip K Knop, Asger Lund, Henrik Vestergaard, Jens J Holst, Tina Vilsbøll. J Clin Endocrinol Metab 2011
140
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.